Multidrug resistant tuberculosis

We read with interest the report by White and Moore-Gillon on the resource implications of multidrug resistant tuberculosis (MDR-TB) in the UK.1 We studied the outcome of 44 HIV negative patients with MDR-TB admitted to two tertiary care tuberculosis units in the Netherlands between 1985 and 1998.2 Most (38 patients) had pulmonary tuberculosis. The mean admission period was 164 days and all patients received an individually tailored combination of antituberculosis drugs for a mean period of 608 days. We estimated the cost of treatment per patient to be US$60 000 which included admission fee, costs for outpatient visits, and the cost of drug provision. Although we did not include cost of toxicity monitoring and additional procedures, our costs compare favourably with those of White et al (mean £60 000) and Mahmoudi (mean US$180 000). In the Netherlands the number of patients with tuberculosis resistant to any antituberculous drugs is limited to 11%, and only 0.6% of the bacilli are MDR. Between 1993 and 1997 only 43 cases of MDR-TB were identified, of which 28% had received previous treatment for tuberculosis (Index Tuberculosis 1998, Royal Netherlands Tuberculosis Association, The Hague, 2000). This suggests that transmission of MDR bacilli rather than inadequate treatment contributes to the resistance problem in the Netherlands. In poor resource countries, directly observed short course chemotherapy of tuberculosis is generally recommended to prevent the occurrence of MDR-TB. We feel that new rapid molecular methods for detecting resistance should be developed to limit the period of contagiousness (nosocomial and community) transmission of MDR bacilli and thus prevent the emergence of MDR-TB. Such tests should then be made available to poor resource countries at an affordable price.

W A GEEGLIS
Department of Internal Medicine, Groningen University Hospital, 9700 RB Groningen, the Netherlands

R VAN ALTENA
Tuberculosis Unit, Beatrixoord, 9750 RA Haren, the Netherlands

T S VAN DER WERF
Respiratory & Intensive Care Unit, Department of Internal Medicine, Groningen University Hospital, 9700 RB Groningen, the Netherlands

Correspondence to: Dr T S van der Werf


Cost of physiotherapy in CF

Increasing survival is associated with increasing numbers of adults with cystic fibrosis (CF). It is recognised that management at specialist CF units is associated with improved health outcomes.3 Assessment of the allocation of staff and resources to adults with CF and accurately determining these costs are essential to enable evaluation of the cost effectiveness of the existing CF services and prediction of future requirements. Global costs of care for young people with CF have been estimated, but studies of the cost of providing physiotherapy for a CF service are scarce.4,5

The cost and utilisation of providing a physiotherapy service to CF patients was determined from February to June 1999 (late summer, autumn and early winter). Using staff designation (pay level), time of physiotherapy (in 5 minute unit allotments), and after hours, compari- son was made with actual funding for the service. At the time of the study the Adult CF Unit at the Prince Charles Hospital in Brisbane provided clinical care for 120 adults with CF from throughout Queensland, with patients travelling up to 1800 km. Despite an active home intravenous antibiotic programme, many patients require admission for treatment of pulmonary exacerbations. Physiotherapy management included respiratory therapy, education, and exercise and was available to all inpatients with CF on a 24 hour basis when required. Outpatient and domiciliary physiotherapy service provision was excluded from this analysis.

During the 5 month study period (150 days) there were 102 inpatient admissions in 58 patients (mean length of stay 12.1 days). Two patients (with two admissions each) were inpatients for a total of 116 and 129 days, respectively, and two patients died during the study. In 5 months 1498 hours of physiotherapy were provided at a cost of £3 700 (£AUD3370) per day, equating to £12 (£AUD32) per patient per day. This involved a mean of 9.9 hours of physiotherapy per day. This cost exceeded funding for the service by 28% (£630/month). The total time of physiotherapy varied from 233 to 401 hours per month. The majority of the service was provided during normal working hours (72.9%). Due to penalty wage rates for after hours’ work, only 58.5% of the total cost was provided during normal working hours. The weekend and public holiday physiotherapy used 22.8% and 3.3% of the time butused 22.8% and 3.3% of the time but accounted for 33.6% and 6.8% of cost, respectively. Physiotherapy care provided during weekday evenings amounted to 1% of total time and total cost.

This analysis shows that the cost of inpatient physiotherapy in a tertiary referral service is £92 (£AUD253) per day or £12 per hour’s work, only 58.5% of the total cost was provided during normal working hours. The weekend and public holiday physiotherapy used 22.8% and 3.3% of the time but accounted for 33.6% and 6.8% of cost, respectively. Physiotherapy care provided during weekday evenings amounted to 1% of total time and total cost.

This analysis shows that the cost of inpatient physiotherapy in a tertiary referral service is £92 (£AUD253) per day or £12 per patient per day. Provision of a service outside normal working hours accounts for a significant proportion of the cost of this service. Regular analysis of time utilisation is required to determine if adequate staffing levels and funding are available to meet the challenge of an increasing population of adults with CF.

Systemic effects of inhaled steroids

The recent article by Harrison and colleagues has limitations which were not adequately addressed.1 It was perhaps hardly surprising to find no differences in plasma budesonide concentrations between normal and asthmatic subjects with budesonide (80.00 mg) during a relatively insensitive assay compared with fluticasone. The respective dry powder inhaler devices for each drug differ markedly in their fine particle dose delivery which might impact on peripheral lung deposition and, in turn, systemic absorption. The fine particle dose expressed as a percentage of the nominal dose for fluticasone Accuhaler (Diskus) is 12% compared with 40% for budesonide Turbuhaler. Moreover, there is a much higher proportion of coarse particles from the Accuhaler than from the Turbuhaler. The study was therefore biased towards showing greater attenuation of peripheral lung absorption with fluticasone Accuhaler in asthmatic subjects.

The authors state that they are unaware of any previous direct comparisons of the effects of fluticasone and budesonide on osteocalcin concentrations. In adult asthmatic subjects steady state dosing for 12 days showed greater percentage suppression with fluticasone than budesonide for mean 08.00 hour serum osteocalcin levels (37% v 20%) which was mirrored by suppression of 08.00 hour serum osteocalcin levels (37% v 12%).1 This would be consistent with the hypothesis of Harrison et al that fluticasone and budesonide may have differential effects on the HPA axis and bone metabolism. Finally, it is worth noting that a meta-analysis of 21 studies evaluating dose related suppression of urinary cortisol levels showed a 4.3-fold (p<0.001) difference in slope when comparing fluticasone and budesonide.1

B J LIPWORTH
Asthma and Allergy Research Group, Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK


www.thoraxjnl.com

Authors’ reply We thank Professor Lipworth for his interest in our paper. The main hypothesis being tested was a comparison of the total cortisol metabolite levels after 7 days of treatment with fluticasone propionate and budesonide between healthy and asthmatic subjects. Although we were interested in the plasma levels of the two drugs, limitations in the assays available prevented us from studying this in more detail. Brutsche et al have, however, also shown markedly lower fluticasone plasma levels in subjects with asthma compared with healthy controls, and we now have data confirming that budesonide plasma levels are identical in healthy and asthmatic subjects.

We accept that part of the explanation for the difference between fluticasone and budesonide may have resulted from differences in the inhalers used. We used dry powder inhalers because we wanted to reduce the effects of inhaler technique and because dry powder inhalers had been used in a number of studies comparing fluticasone and budesonide in healthy subjects. It is also worth noting that Brutsche et al studied metered dose inhalers in a large volume spacer and produced similar results to ours.

We are grateful to Professor Lipworth for bringing our attention to his letter reporting a study in subjects with mild asthma. This approach was identical to the later publication that we had referenced in which the osteocalcin data were omitted. The reduction in osteocalcin concentrations with budesonide but not fluticasone at microgram equivalent doses was an unexpected finding and we did state that confirmation of this finding was required.

Finally, we have major reservations about the meta-analysis published by Lipworth, not only because it combined studies performed in healthy and asthmatic subjects but because it included a number of studies which did not satisfy the methodology for a meta-analysis.

The study by Harrison and colleagues suggests that inhaled fluticasone in a dose of 1500 µg/day can cause pituitary suppression as measured by urinary total cortisol metabolites (TCM) in healthy subjects compared with asthmatics, but that budesonide in a dose of 1600 µg/day may do so. For fluticasone, the mean difference between healthy and asthmatic TCM after 7 days treatment with fluticasone was significant but the same comparison for budesonide was not. The confidence interval for the mean difference in TCM between the healthy and asthmatic subjects given budesonide was positive but with a p value of 0.2. Is this explained by the omission of a sign?

However, when change from baseline is examined in healthy subjects, both drugs suppress TCM and the difference between them was not significant. If equipotent dosages of fluticasone/day and 1600 µg budesonide/day had been given, would the urinary TCM be significantly different for healthy subjects? This is of practical importance if inhaled corticosteroids are considered for treating patients who do not have asthma. Children with isolated persistent cough, which is not asthma, are often prescribed inhaled corticosteroids. Adrenal crises in patients believed to have asthma who have been prescribed inhaled steroids must be examined carefully.

This paper and others which have reported systemic effects of inhaled steroids in healthy subjects should be anti-discriminative in their use of these drugs in patients who do not have asthma.

S A MCKENZIE
Fielden House
Royal London Hospital
London E1 1BB, UK
mckenzie@rlh.nhct.demon.co.uk

Pulmonary infiltrates in non-HIV patients

We read with interest the article by Rano et al in the May edition of Thorax. This group showed that, by using non-invasive methods (blood cultures, sputum cultures, nasopharyngeal washes and tracheobronchial aspirates), they were able to make a positive diagnosis in 41% of 200 non-HIV immunocompromised patients with pulmonary infiltrates.

We have looked at a similar group of patients treated in the Leukaemia and Lymphoma Units at the Royal Marsden Hospital who needed investigation for pulmonary infiltrates and found a low diagnostic yield from bronchoscopy with neither a positive result (36%) nor a change in management (28%) making any impact on survival. Like Rano et al, we are therefore keen to explore the use of non-invasive investigations.

From our literature review we found many groups advocating the use of high resolution CT scanning (HRCT) of the chest. It has found particular use in those patients with a normal chest radiograph but respiratory symptoms and fever, having a negative predictive value after bone marrow transplantation of 97%. The HRCT scan has characteristic appearances in aspergillosis, Pneumocystis carinii pneumonia (PCP) and cytomegalovirus (CMV) infection. One group has compared HRCT and bronchoalveolar lavage (BAL) in the diagnosis of fungal pneumonia and found the former to be superior. From these data we concluded that such characteristic appearances on CT scanning could obviate the need for bronchoscopy.

The paper by Rano et al reports 15% of one group of patients who showed the characteristic appearances on CT scanning and were not subsequently investigated for fungal infections. The authors state that in these cases the HRCT was suggestive of fungal infection. Were the authors aware that on reviewing the data 10 of these patients were found to have A fumigatus and four (2%) were PCP.

Do the authors feel that these patients might have been diagnosed by HRCT scanning and thus have avoided bronchoscopy altogether?

Antifungal treatment was only instigated after 4–5 days if there was no improvement or positive microbiology. With such a policy the mortality rate in those with Aspergillus infections was 67%. Other groups recommend early introduction of antifungal treatment due to its high prevalence, particularly in haematological malignancies. In the light of these results and the potential of early HRCT scanning, have the group reviewed their practice to include early use of antifungal treatment?

P MURRAY
M O’BRIEN
Lung Unit,
Royal Marsden Hospital,
Douglas Road,
Sutton, Surrey SM2 5PT, UK

AUTHORS’ REPLY We appreciate the valuable comments by Drs Murray and O’Brien regarding our study on immunocompromised patients. In our study the diagnostic yield of non-invasive methods was 41%. The good results obtained with these techniques, as well as their availability and relatively low cost, make them very useful in the clinical management of immunocompromised patients. In this sense, HRCT scanning, as Drs Murray and O’Brien point out, has a demonstrated role in the diagnosis of some pulmonary complications, particularly Aspergillus pneumonia, and can be included in the diagnostic strategies of non-invasive diagnostic techniques. Whether or not an HRCT scan might facilitate the early start of antifungal treatment and/or cytomegalovirus (CMV) antiproteinase activity, most commonly caused by cigarette smoking. Congenital deficiency of α-antitrypsin, the most well known antiproteinase, is an important risk factor for the development of premature emphysema. In addition, various other causes have been reported including intravenous drug abuse, particularly Ritalin. More recently, Johnson et al reported four cases of bullous emphysema associated with marijuana smoking. We want to report an additional case of severe premature bullous emphysema in a man with a longstanding history of cocaine smoking. To the best of our knowledge, this relationship has only once been reported in the Spanish medical literature.

Severe bullous emphysema associated with cocaine smoking

Pulmonary emphysema is characterised by permanent enlargement of airspaces distal to the terminal bronchiolo accompanied by destruction of alveolar walls. The loss of elastic tissue contained in the interalveolar septa is caused by an imbalance between proteinase and antiproteinase activity, most commonly caused by cigarette smoking. Congenital deficiency of α-antitrypsin, the most well known antiproteinase, is an important risk factor for the development of premature emphysema. In addition, various other causes have been reported including intravenous drug abuse, particularly Ritalin. More recently, Johnson et al reported four cases of bullous emphysema associated with marijuana smoking. We want to report an additional case of severe premature bullous emphysema in a man with a longstanding history of cocaine smoking. To the best of our knowledge, this relationship has only once been reported in the Spanish medical literature.

A 40 year old man was admitted with progressive dyspnoea, cough, and fever. According to his relatives he had been smoking cocaine (so called “free basing”) for the past 17 years. A reliable history of tobacco smoking could not be obtained because of his respiratory distress and poor level of consciousness. His medical history consisted of recurrent respiratory tract infections. Chest
Side effects of antituberculous treatment

Combined antimonybacterial chemotherapy has been shown to be very effective in the treatment of Mycobacterium tuberculosis hominis (MTH) pulmonary infections with a cure rate of >95% for short term (6 month) courses.1 Recent WHO initiatives have been launched and are aimed at eradicating pulmonary tuberculosis by intensive adoption of directly observed treatment (DOT) strategies in countries in which the incidence is high.

A new drug formulation has recently been produced which provides the three main first line drugs in the same tablet in a fixed ratio (rifampin (RIF) 120 mg, isoniazid (INH) 50 mg, and pyrazinamide (PZM) 300 mg).2 This formulation is likely to be extremely useful, particularly in developing countries where it can provide reliable simultaneous administration of all the drugs needed on bi-weekly or tri-weekly DOT programmes.3 However, it is not intended to substitute any (or all) of the single components in countries where they are already available and marketed.

In a recent WHO report, of all the industrialised European countries, Italy reported the highest prevalence of multidrug resistance among previously treated cases of tuberculosis (33.9%, 95% CI 27.6 to 42.7), with any drug resistance accounting for up to 60.6% of the strains.4 In addition, there was a high prevalence of resistance in new cases of tuberculosis with 12.3% resistance to any drug.5 In Italy the distribution and marketing of PZM ceased as a single drug formulation between 15 June 2000 and early 2001. This abrupt policy change temporarily introduced a new and interesting challenge to the treatment of MTH, and possibly increased risks of toxicity and decreased treatment efficiency for some patients.

Over the last 2 years we have treated 26 patients with pulmonary tuberculosis using the standard four drug regimens administered as single drugs and have recorded a relatively high rate of hepatotoxicity (35%) compared with reports from North America and European analyses (11%).6,7 In eight of the nine patients with hepatotoxicity the substitution of INH led to normalisation of liver function. This incidence of side effects approaches the incidence of side effects (26%) reported in a European study of similar design on 591 patients of similar mean age.

In our 26 patients we estimated that, if a fixed dose formulation had been used to maintain the dose of RIF at 10 mg/kg/day, a significantly increased dose of PZM (not correlated to the one that was actually given) would have been administered. Thus, it is reasonable to suggest that the already high rate of toxicity could increase in incidence and severity when PZM is administered as a fixed dose formulation. When considered in the context of the unavailability of PZM single drug formulations, two additional considerations are warranted.

Firstly, there is a limited choice of first line regimens which exclude INH for patients with INH related hepatotoxicity (for example, RIF+STM+EMB but not RIF+PZM+STM). Side effects in hospital treated patients usually lead to withdrawal of one of the basic drugs and replacement by other drugs such as ethambutol or streptomycin. This may lead to more prolonged treatment and to decreased adherence.8 However, these negative consequences would be considerably enhanced if single drug formulations of PZM are not available since withdrawal of at least two first line drugs would be needed (PZM + INH).

Secondly, the treatment of patients with chronic tuberculosis who are infected with the most frequent INH or RIF resistant MTH (43.3% and 44.9%, respectively) or with multidrug resistant MTH could lead to the drug being acquired from abroad at high cost, and sometimes to interruptions in the supply with dangerous consequences for the patient’s health. In fact, most tuberculosis units in our area acquired PZM as a single drug formulation from neighbouring countries during the time when it was not available.

Thus, available data do not support the use of fixed dose formulations as the only treatment choice in developed countries. This could be particularly dangerous where there is a high prevalence of multiple drug resistant MTH, including developing countries.

NOTICE

Basic and Clinical Allergy 2002

“Basic and Clinical Allergy 2002” will be held at the National Heart & Lung Institute, Faculty of Medicine, Imperial College, London on 18–22 March 2002. Main topics include: Basic cellular mechanisms and their application in allergic disease; Allergic rhinitis; Indoor allergens; Allergen specific immunotherapy and T cell tolerance; Asthma (aetiology and pathogenesis); Treatment of asthma. CPD/CME approval pending (2001 course maximum 23.5 credits). Further details from the Short Courses Office, Education Centre, Faculty of Medicine, Imperial College, National Heart & Lung Institute, Dovehouse Street, London SW3 6LY, UK. Telephone: +44 (0)20 7351 8172. Fax +44 (0)20 7351 8246. Email: shortcourses.nhli@ic.ac.uk; website: www.med.ic.ac.uk/divisions/47a/mtgs.htm.
Pulmonary infiltrates in non-HIV patients

P MURRAY and M O'BRIEN

*Thorax* 2001 56: 981-982
doi: 10.1136/thorax.56.12.981

Updated information and services can be found at:
http://thorax.bmj.com/content/56/12/981

These include:

References
This article cites 11 articles, 3 of which you can access for free at:
http://thorax.bmj.com/content/56/12/981#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/